Q2 FY2026 EarningsPALI.US Q2 FY26 results beat consensus across all major profitability metrics, driven by a surprise $0.5M license revenue milestone and higher-than-expected interest income. GAAP Net Loss was $10.57M vs. $11.39M expected, resulting in a GAAP EPS of -$0.05 compared to the -$0.0525 consensus. The company ended the period with a robust $125.2M cash position, providing a runway into 2028 following the recent FDA clearance for Phase 2 clinical trials in Ulcerative Colitis.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Palisade Bio(PALI) the Revenue is 500 K (--%), Beat estimate;the EBIT is -11.7 M (-311.5%), Beat estimate;the EPS is -0.05 (+91.38%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.01B311.47%
-0.01B321.64%
+0.00B10.17%
EPSExceed expectations
-0.0591.38%
-0.052590.95%
+0.00250.43%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf